The company highlighted the results from a planned interim analysis of the P-III trial evaluating Imfinzi + Pt-based CT & bevacizumab vs CT + bevacizumab in a ratio (1:1:1) in ~1200 patients at 179 study locations, followed by maintenance treatment with Imfinzi & bevacizumab with/out Lynparza
Lynparza, Imfinzi, CT & bevacizumab achieved an improvement in PFS. Imfinzi, CT + bevacizumab showed a numerical improvement in PFS but did not reach statistical significance at this interim analysis while OS & other 2EPs are immature and will be formally assessed at a subsequent analysis
The safety & tolerability were consistent with prior trials & known profiles of the individual therapies. The results will be shared with health authorities
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca and Merck Receive EC’s Approval of Lynparza (olaparib) for Metastatic Castration-Resistant Prostate Cancer
